Brokerages Anticipate Albireo Pharma Inc (ALBO) to Post -$0.97 Earnings Per Share

Brokerages forecast that Albireo Pharma Inc (NASDAQ:ALBO) will report earnings per share of ($0.97) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Albireo Pharma’s earnings, with estimates ranging from ($1.08) to ($0.68). Albireo Pharma posted earnings of ($0.73) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 32.9%. The business is scheduled to announce its next earnings results on Tuesday, November 13th.

On average, analysts expect that Albireo Pharma will report full year earnings of ($3.39) per share for the current fiscal year, with EPS estimates ranging from ($3.70) to ($2.75). For the next fiscal year, analysts forecast that the business will post earnings of ($3.95) per share, with EPS estimates ranging from ($6.06) to ($2.13). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Albireo Pharma.

Albireo Pharma (NASDAQ:ALBO) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.98) by ($0.24). The business had revenue of $0.73 million during the quarter, compared to analyst estimates of $2.00 million.

A number of equities analysts recently weighed in on ALBO shares. Wedbush reaffirmed an “outperform” rating and issued a $69.00 price target on shares of Albireo Pharma in a report on Tuesday, August 7th. BidaskClub raised Albireo Pharma from a “sell” rating to a “hold” rating in a report on Saturday, September 1st. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a report on Wednesday, August 8th. Finally, Zacks Investment Research raised Albireo Pharma from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a report on Tuesday, July 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Albireo Pharma presently has a consensus rating of “Buy” and an average target price of $59.40.

In other Albireo Pharma news, insider Ronald Harold Wilfred Cooper purchased 788 shares of Albireo Pharma stock in a transaction that occurred on Tuesday, August 14th. The stock was bought at an average price of $31.85 per share, with a total value of $25,097.80. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 3.60% of the company’s stock.

Several institutional investors have recently made changes to their positions in the business. Federated Investors Inc. PA raised its holdings in shares of Albireo Pharma by 89.1% during the second quarter. Federated Investors Inc. PA now owns 586,146 shares of the biopharmaceutical company’s stock valued at $20,808,000 after acquiring an additional 276,221 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Albireo Pharma by 582.8% during the second quarter. BlackRock Inc. now owns 524,276 shares of the biopharmaceutical company’s stock valued at $18,611,000 after acquiring an additional 447,496 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Albireo Pharma by 234.0% during the first quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock valued at $5,068,000 after acquiring an additional 109,017 shares during the last quarter. Chicago Capital LLC raised its holdings in shares of Albireo Pharma by 48.4% during the second quarter. Chicago Capital LLC now owns 134,748 shares of the biopharmaceutical company’s stock valued at $4,784,000 after acquiring an additional 43,917 shares during the last quarter. Finally, Heartland Advisors Inc. raised its holdings in shares of Albireo Pharma by 36.9% during the second quarter. Heartland Advisors Inc. now owns 125,000 shares of the biopharmaceutical company’s stock valued at $4,438,000 after acquiring an additional 33,677 shares during the last quarter. 63.41% of the stock is owned by institutional investors and hedge funds.

Shares of ALBO stock traded up $1.03 on Friday, hitting $33.29. The company had a trading volume of 91,400 shares, compared to its average volume of 71,796. The stock has a market cap of $386.15 million, a PE ratio of -10.20 and a beta of 1.29. Albireo Pharma has a twelve month low of $20.27 and a twelve month high of $39.87.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Albireo Pharma (ALBO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply